Canada Markets open in 4 hrs 45 mins

Adagio Therapeutics, Inc. (ADGI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.44+0.89 (+16.04%)
At close: 04:00PM EST
6.17 -0.27 (-4.19%)
Pre-Market: 04:41AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.55
Open5.62
Bid0.00 x 2200
Ask0.00 x 2200
Day's Range5.62 - 6.99
52 Week Range4.92 - 78.82
Volume9,354,270
Avg. Volume8,130,467
Market Cap716.463M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-14.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • Motley Fool

    Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

    The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19.

  • GlobeNewswire

    Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

    Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway to Address Omicron and Potential Future SARS-CoV-2 Variants WALTHAM, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious d

  • GlobeNewswire

    Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., chief executive officer of Adagio, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 a.m. ET. A live webcast will be